BR112021019959A2 - Anticorpo biespecífico, e, formulação farmacêutica - Google Patents

Anticorpo biespecífico, e, formulação farmacêutica

Info

Publication number
BR112021019959A2
BR112021019959A2 BR112021019959A BR112021019959A BR112021019959A2 BR 112021019959 A2 BR112021019959 A2 BR 112021019959A2 BR 112021019959 A BR112021019959 A BR 112021019959A BR 112021019959 A BR112021019959 A BR 112021019959A BR 112021019959 A2 BR112021019959 A2 BR 112021019959A2
Authority
BR
Brazil
Prior art keywords
bispecific antibody
pharmaceutical formulation
site capable
antigen binding
binding site
Prior art date
Application number
BR112021019959A
Other languages
English (en)
Portuguese (pt)
Inventor
Henrik Østergaard
Jens Breinholt
S Gandhi Prafull
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112021019959A2 publication Critical patent/BR112021019959A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112021019959A 2019-04-17 2020-04-15 Anticorpo biespecífico, e, formulação farmacêutica BR112021019959A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19169704 2019-04-17
EP19213867 2019-12-05
PCT/EP2020/060579 WO2020212415A1 (en) 2019-04-17 2020-04-15 Bispecific antibodies

Publications (1)

Publication Number Publication Date
BR112021019959A2 true BR112021019959A2 (pt) 2022-02-08

Family

ID=70189980

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019959A BR112021019959A2 (pt) 2019-04-17 2020-04-15 Anticorpo biespecífico, e, formulação farmacêutica

Country Status (19)

Country Link
US (3) US11325983B2 (cg-RX-API-DMAC7.html)
EP (1) EP3956359A1 (cg-RX-API-DMAC7.html)
JP (3) JP7297928B2 (cg-RX-API-DMAC7.html)
KR (2) KR102652906B1 (cg-RX-API-DMAC7.html)
CN (1) CN113692415B (cg-RX-API-DMAC7.html)
AU (1) AU2020259982B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019959A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135632A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002710A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014072A2 (cg-RX-API-DMAC7.html)
IL (1) IL286757A (cg-RX-API-DMAC7.html)
MA (1) MA55705A (cg-RX-API-DMAC7.html)
MX (1) MX2021012365A (cg-RX-API-DMAC7.html)
MY (1) MY206180A (cg-RX-API-DMAC7.html)
PE (1) PE20212262A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552586A1 (cg-RX-API-DMAC7.html)
SA (1) SA521430592B1 (cg-RX-API-DMAC7.html)
WO (1) WO2020212415A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107426B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212262A1 (es) * 2019-04-17 2021-11-29 Novo Nordisk As Anticuerpos biespecificos
CN116137870B (zh) 2020-10-12 2025-02-18 日本制铁株式会社 热浸镀锌钢板
JP2025506341A (ja) * 2022-02-03 2025-03-11 アイジーエム バイオサイエンシズ インコーポレイテッド 抗cd38結合分子及びその使用
CN118786148A (zh) * 2022-03-02 2024-10-15 诺和诺德医疗保健公司 每周一次施用fviii模拟双特异性抗体的方法
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
TW202546001A (zh) * 2024-02-08 2025-12-01 丹麥商赫邁博私人有限責任公司 用於治療凝血病變的方法
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541275B1 (en) 1988-02-03 2003-04-01 Dade Behring Inc. Immunoassay for F1.2 prothrombin fragment
TW212184B (cg-RX-API-DMAC7.html) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH05168494A (ja) 1991-05-17 1993-07-02 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
EP0771216B9 (en) 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
DE19802139C1 (de) 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
US20040180409A1 (en) 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
DE10354403A1 (de) 2003-11-20 2005-06-23 Dade Behring Marburg Gmbh Gegen das Prothrombin-Fragment F 1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
ES2353084T3 (es) 2006-04-07 2011-02-25 Novo Nordisk Health Care Ag Complejo covalente de factor vii y factor tisular.
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN102361884A (zh) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
WO2011023785A1 (en) 2009-08-27 2011-03-03 Novo Nordisk A/S Targeting tissue factor to activated platelets
CN103153327B (zh) 2010-04-08 2016-01-20 国家健康与医学研究院 衍生自trem样转录1(tlt-1)的抑制肽和其用途
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
AU2012222366A1 (en) * 2011-03-02 2013-08-01 Novo Nordisk A/S Coagulation factor-targeting to TLT-1 on activated platelets
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
AU2018216008A1 (en) * 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
PE20212262A1 (es) * 2019-04-17 2021-11-29 Novo Nordisk As Anticuerpos biespecificos

Also Published As

Publication number Publication date
ZA202107426B (en) 2025-03-26
MA55705A (fr) 2022-02-23
JP2025029155A (ja) 2025-03-05
CN113692415A (zh) 2021-11-23
EP3956359A1 (en) 2022-02-23
JP2023116676A (ja) 2023-08-22
US20220064329A1 (en) 2022-03-03
KR20240046282A (ko) 2024-04-08
KR102652906B1 (ko) 2024-04-01
CO2021014072A2 (es) 2022-01-17
SA521430592B1 (ar) 2024-08-05
JP7882929B2 (ja) 2026-06-30
US12122847B2 (en) 2024-10-22
KR20210153639A (ko) 2021-12-17
WO2020212415A1 (en) 2020-10-22
IL286757A (en) 2021-10-31
US20220213218A1 (en) 2022-07-07
PH12021552586A1 (en) 2023-07-31
US20250002607A1 (en) 2025-01-02
MX2021012365A (es) 2021-11-17
MY206180A (en) 2024-12-03
JP7297928B2 (ja) 2023-06-26
CA3135632A1 (en) 2020-10-22
CL2021002710A1 (es) 2022-05-27
CN113692415B (zh) 2025-01-07
PE20212262A1 (es) 2021-11-29
JP2022529036A (ja) 2022-06-16
AU2020259982B2 (en) 2026-05-14
JP7601952B2 (ja) 2024-12-17
AU2020259982A1 (en) 2021-10-28
US11325983B2 (en) 2022-05-10

Similar Documents

Publication Publication Date Title
WO2019171253A8 (en) Anti-pd-1 antibody compositions
PL3882275T3 (pl) Przeciwciało dwufunkcyjne anty-pd-1 i anty-vegfa, kompozycja farmaceutyczna i zastosowanie tych przeciwciał
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
MX2025010757A (es) Formulacion farmaceutica de ph bajo
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
EA202192405A1 (ru) Составы антител против il-36r
SA521430592B1 (ar) أجسام مضادة ثنائية النوعية
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
MX381232B (es) Formulación de anticuerpos.
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
EP4406554A3 (en) Anti-cd3 antibody formulations
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MX2019007347A (es) Anticuerpo anti-cd3 y moleculas que comprenden el anticuerpo.
ECSP10010056A (es) ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
MX2021004774A (es) Formulacion de anticuerpos.
MX2021009851A (es) Formulacion de anticuerpos terapeuticos.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2021005085A (es) Formulacion de anticuerpo.
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
MX2023004533A (es) Formulaciones de anticuerpos anti-siglec-8.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]